Methods Of Treating Plantar Fibromatosis
Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.
1 . A method of treating moderate to severe plantar fibromatosis in a subject or a population of subjects, the method comprising:
intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis, wherein the dose of collagenase administered per nodule comprises about 0.45 mg to about 1.35 mg and the treating comprises:
a reduction from baseline as measured on a foot function index (FFI) pain sub scale;
a reduction from baseline as measured on a FFI combined pain and difficulty subscale;
a reduction from baseline in LSM FFI Foot Pain score;
a reduction from baseline in combined FFI pain and Difficulty score;
or any combination thereof.
2 . The method of claim 1 , wherein the reduction or improvement occurs at Day 57 or earlier.
3 . The method of claim 1 , wherein the reduction or improvement is an at least 1 point reduction from baseline or an at least 1 point improvement from baseline.
4 . The method of claim 1 , wherein the collagenase comprises collagenase I activity, collagenase II activity, or a mixture of collagenase I activity and collagenase II activity.
5 . The method of claim 1 , wherein the subject has an NRS score of ≥5 and <10 prior to treatment.
6 . The method of claim 1 , wherein, prior to the injecting, the plantar fibromatosis nodules are hard or firm.
7 . The method of claim 1 , wherein, prior to injecting, the subject had an NRS score of less than 10 and did not have moderately firm plantar fibromatosis nodule(s).
8 . The method of claim 1 , wherein the collagenase has a concentration of about 0.6 mg/ml to about 2.25 mg/ml.
9 . The method of claim 1 , wherein the collagenase has a potency of about 500 SRC units/mg to about 30,000 SRC units/mg.
10 . The method of claim 1 , wherein about 5 SRC units to about 180,000 SRC units of collagenase are administered per nodule.
11 . The method of claim 1 , wherein the collagenase has a potency of about 10,000 GPA units/mg to about 400,000 GPA units/mg.
12 . The method of claim 1 , wherein about 1,000 GPA units to about 2,400,000 GPA units of collagenase are administered per nodule.
13 . A method of treating moderate to severe plantar fibromatosis in a subject or a population of subjects, the method comprising:
intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis, wherein the dose of collagenase administered per nodule comprises about 0.6 mg, and the treating comprises:
a reduction from baseline in the weekly mean of the average daily pain (ADP) score;
a reduction from baseline in the weekly mean of the ADP score;
a reduction from baseline on the FFI Pain Subscale score;
an improvement from baseline on the PGIS Foot Pain Subscale;
a reduction from baseline in LSM FFI Foot Pain score;
a reduction from baseline in combined FFI pain and Difficulty score;
or any combination thereof.
14 . The method of claim 13 , wherein the reduction or improvement occurs at Day 85 or earlier.
15 . The method of claim 13 , wherein the reduction or improvement is an at least 1 point reduction from baseline or an at least 1 point improvement from baseline.
16 . The method of claim 13 , wherein the collagenase comprises collagenase I activity, collagenase II activity, or a mixture of collagenase I activity and collagenase II activity.
17 . The method of claim 13 , wherein the subject had an NRS score of 5 to 9 prior to treatment.
18 . The method of claim 13 , wherein the subject had an average daily pain (ADP) score on the Pain Intensity NRS of 5 to 9 during the 7 days prior to treatment.
19 . The method of claim 13 , wherein, prior to the injecting, the plantar fibromatosis nodules are hard or firm.
20 . The method of claim 13 , wherein, prior to injecting, the subject had an NRS score of less than or equal to 9 and did not have moderately firm plantar fibromatosis nodule(s).
21 . The method of claim 13 , wherein the plantar fibromatosis nodule is less than or equal to 4 cm in size.
22 . The method of claim 21 , comprising administering a single injection of the collagenase to any nodule that is less than 2 cm in size.
23 . The method of claim 21 , comprising administering two injections of the collagenase to any nodule that is greater than 2 cm but less than 4 cm in size.
24 . The method of claim 23 , wherein each of the two injections comprises 0.3 mg of the collagenase.
25 . The method of claim 13 , wherein the collagenase has a concentration of about 0.6 mg/ml to about 2.25 mg/ml.
26 . The method of claim 13 , wherein the collagenase has a potency of about 500 SRC units/mg to about 30,000 SRC units/mg.
27 . The method of claim 13 , wherein about 5 SRC units to about 180,000 SRC units of collagenase are administered per nodule.
28 . The method of claim 13 , wherein the collagenase has a potency of about 10,000 GPA units/mg to about 400,000 GPA units/mg.
29 . The method of claim 13 , wherein about 1,000 GPA units to about 2,400,000 GPA units of collagenase are administered per nodule.